Coronavirus Mpro Stabilization via Disulfide Bond Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective strategies to inhibit the main protease (Mpro) enzyme of coronaviruses, such as SARS-CoV-2, which is crucial for viral replication, and existing therapeutics often target the reduced conformation of the enzyme, neglecting its oxidized state that may provide protective mechanisms against immune response.
Innovation Solution
A modified coronavirus Mpro enzyme with a disulfide bond between Cys145 and Cys117 is engineered to stabilize an oxidized conformation, allowing for the identification of compounds that bind and reduce Mpro activity, using site-specific mutations like H163A, F140A, or N28A to create a stable, inactive conformation for therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutics target the reduced conformation of Mpro, then they can inhibit viral replication, but they neglect the oxidized state which may provide protective mechanisms against immune response
Solution Approach 1:
The patent applies parameter changes by modifying the redox state parameter of Mpro to access different conformational states. By engineering cysteine mutations (C145S, C117S) that prevent disulfide bond formation, the patent stabilizes the reduced conformation for therapeutic targeting, while separately addressing the oxidized state through compounds that can penetrate and inhibit both conformations
Solution Approach 2:
Instead of targeting the native oxidized conformation directly, the patent inverts the approach by creating a stabilized reduced conformation through mutation that serves as a proxy target. This allows screening and identification of compounds that can then be evaluated against both reduced and oxidized forms, effectively targeting the previously neglected oxidized state through an indirect approach
2Ease of manufacture
If Mpro is engineered with site-specific mutations to stabilize oxidized conformation, then compounds can be identified that bind and reduce Mpro activity, but the enzyme's natural catalytic function is altered
Solution Approach 1:
The patent segments the Mpro enzyme into different conformational states (reduced and oxidized) that can be independently stabilized through specific mutations. The C145S/C117S mutations segment out the oxidized conformation stabilization, allowing separate study and drug development for each state without the complications of dynamic interconversion
Solution Approach 2:
The mutated Mpro enzyme serves as an intermediary target that mimics the native enzyme's binding properties while stabilizing a specific conformation. Compounds identified through this intermediary target are then validated against native Mpro, allowing the intermediary to facilitate drug discovery without requiring permanent alteration of the native enzyme's function
3Manufacturing precision
If compounds are screened against modified Mpro with disulfide bond, then inhibitors can be identified that stabilize inactive conformation, but the screening process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the oxidized conformation through genetic mutation before the screening process begins. This eliminates the need for complex real-time maintenance of oxidized conditions during screening, as the conformation is locked in place by the mutation, simplifying the screening workflow while maintaining specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the development of compounds that can effectively inhibit Mpro activity by targeting the oxidized conformation, potentially offering a broader spectrum of antiviral efficacy against coronaviruses by stabilizing an inactive state, thereby reducing viral replication and spread.
Implementation Method 1
identifying compounds that bind to and stabilize a modified Mpro in an oxidized conformation with a disulfide bond formed between Cys145 (C145) and Cys117 (C117) of Mpro
Data Source
AI summary
A method of identifying compounds that reduce main protease (Mpro) activity of a coronavirus is described, which comprises identifying compounds that bind to and stabilize a modified Mpro in an oxidized conformation with a disulfide bond formed between Cys145 (C145) and Cys117 (C117) of Mpro, reducing the catalytic activity of the modified Mpro. The modified Mpro may comprise substitution of a residue at one or both sites of His163 (H163), and/or Phe140 (F140). A modified Mpro enzyme structure (and its in vitro synthesized form) is described, together with a system for screening or designing compounds useful in treatment or prophylaxis of coronavirus infection such as infection from SARS-CoV-2.